The DOI matches its Crossref record.
Faecal calprotectin: a marker of inflammation throughout the intestinal tract
Abstract
OBJECTIVE: To assess the potential of measuring the calcium-binding protein calprotectin in faeces as a method of screening for alimentary inflammation and neoplasia. SETTING: Hospital day services unit for endoscopy and faecal analysis in the clinical biochemistry department. PARTICIPANTS: Consented patients attending for routine endoscopy were requested to provide faeces. Seventeen of the initial 30 patients provided faeces before and 1 week after endoscopy. After this, 116 patients for planned endoscopy provided faeces before endoscopy. The group comprised 43 patients with upper-gastrointestinal lesions, seven patients with inflammatory bowel disease, seven patients with irritable bowel syndrome, 31 patients with colonic disorders, and 28 normal people. A final 18 patients with known inflammatory bowel disease (seven patients), gastric carcinoma (one patient), colorectal cancer (eight patients) and colorectal adenoma (two patients) had faeces analysed. METHOD: Faeces were analysed by the Nycotest PhiCal enzyme-linked immunosorbent assay (ELISA) (Nycomed, Oslo, Norway), and the final 18 patients were analysed by the newer version marketed as Calprest. RESULTS: No definite differences between pre- and post-endoscopy calprotectin were found, but it was considered preferable in the subsequent patients to analyse pre-endoscopy faeces. Upper-gastrointestinal disorders showed little difference in calprotectin levels, Barrett's oesophagus (median 6.8 mg/l), gastric ulcer (median 6.5 mg/l) or gastritis/duodenitis (median 5.2 mg/l), but these levels were all higher than the median calprotectin level of normal subjects (4.5 mg/l). The oesophageal and gastric carcinoma median was elevated significantly at 30 mg/l. Inflammatory bowel disease was also associated with marked elevation (Crohn's disease, 31.2 mg/l; ulcerative colitis, 116.2 mg/l). Colorectal polyps (median 3.7 mg/l) and adenoma (median 3.8 mg/l) showed no elevated levels in contrast to colorectal carcinoma (median 53.4 mg/l). The elevated calprotectin in inflammatory bowel disease and colorectal carcinoma combined gave a sensitivity of 81.8% and a specificity of 73.2%. CONCLUSIONS: Calprotectin levels are elevated in inflammation and cancer but are not helpful in differentiating between these disorders. In our series, calprotectin was not elevated in colonic polyps or adenomata. Calprotectin could be helpful as a screening method in a general gastroenterology population for inflammatory bowel disease and those with carcinoma, as well as assessing and monitoring disease activity in inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lewis, J. D., Chen, E. Z., Baldassano, R. N., Otley, A. R., Griffiths, A. M., Lee, D., Bittinger, K., Bailey, A., Friedman, E. S., Hoffmann, C., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.09.008 · Cited by 823
van Rheenen, P. F., Van de Vijver, E., & Fidler, V. (2010) · BMJ · doi:10.1136/bmj.c3369 · Cited by 714
Mosli, M. H., Zou, G., Garg, S. K., Feagan, S. G., MacDonald, J. K., Chande, N., Sandborn, W. J., & Feagan, B. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.120 · Cited by 690
Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction
Crenn, P., Messing, B., & Cynober, L. (2008) · Clinical Nutrition · doi:10.1016/j.clnu.2008.02.005 · Cited by 586
Calprotectin: from biomarker to biological function
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H., & Adolph, T. E. (2021) · Gut · doi:10.1136/gutjnl-2021-324855 · Cited by 500
Metadata
- Authors
- Summerton, C. B., Longlands, M. G., Wiener, K., & Shreeve, D. R.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2002-08
- Volume
- 14
- Issue
- 8
- Pages
- 841-845
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2325167162
- Cited by
- 187
- References
- 0
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Faecal calprotectin: a marker of inflammation throughout the intestinal tract. https://app.cochat.ai/papers/10.1097/00042737-200208000-00005
- The paper
- Summerton, C. B., Longlands, M. G., Wiener, K., & Shreeve, D. R. (2002). Faecal calprotectin: a marker of inflammation throughout the intestinal tract. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/00042737-200208000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.